OFFICIAL STOCK MARKET (TTSE) THREAD

[theview868]

If it's 18 mite take a look
Witco btw from the previous post looks promising.
Smoking pays dividends
Got a small thing from em month end and was hmm I forgot I picked these stocks
Wasn't much but next month I go take a some more cash

[pugboy]

it’s odd that they only selling 350k shares at $48
ie raising $16m
why do they want to do that?
the kind of cash they making one would think they could finance a lot more than that if they needed $16m

MEDCORP IPO...any thoughts?

I wouldn't, not for ordinary shares, at that price, considering the data in the prospectus.

price hadda come down to $18 for me to even consider it

[88sins]

it’s odd that they only selling 350k shares at $48
ie raising $16m
why do they want to do that?
the kind of cash they making one would think they could finance a lot more than that if they needed $16m

2 things
1-Read the prospectus and take note of the total share volume.
2-I could tell u sumn, but not here nah

[theview868]

it’s odd that they only selling 350k shares at $48
ie raising $16m
why do they want to do that?
the kind of cash they making one would think they could finance a lot more than that if they needed $16m

2 things
1-Read the prospectus and take note of the total share volume.
2-I could tell u sumn, but not here nah

Tell we or pm please

[pugboy]

350k is a fraction of the total share volume
read that early
first thing i wanted to know how much them fellas had in
i thought dentist camacho was a shareholder but i was wrong

you buying into sumting which you will have little say and hope to get some dividends

it’s odd that they only selling 350k shares at $48
ie raising $16m
why do they want to do that?
the kind of cash they making one would think they could finance a lot more than that if they needed $16m

2 things
1-Read the prospectus and take note of the total share volume.
2-I could tell u sumn, but not here nah

[88sins]

Camacho left years ago.


I not putting my money in people business, especially in people business where I got no control, a lot of risk, and no guarantees when it comes to roi

[pugboy]

fixed

Camacho left years ago.


I not putting my money in people famalee business, especially in people business where I got no control, a lot of risk, and no guarantees when it comes to roi

[88sins]

Of the seven, only 2 pairs are actually related
But I see your point

[theview868]

Of the seven, only 2 pairs are actually related
But I see your point

Tru exactly cat in bag yes

[snatman]

Trinidad Guardian

Around the world, initial public offerings (IPOs) of shares in public companies are popular among investors because they present the potential for high returns, especially if the IPO is priced at a discount to its intrinsic value. IPOs also present an opportunity to invest in companies that are doing different things or doing things differently. And thirdly, IPOs allow for the diversification of an investor’s portfolio.

For most individual local investors, an IPO at this time is particularly useful, given the decline in the local stock market for the last three years.

Last year, according to the Trinidad and Tobago Stock Exchange’s latest annual report, “the local equity market faced a challenging environment, with most listed securities recording year-on-year price declines. This broad-based decline weighed heavily on the market indices.

“The Composite Index fell by 11.60 per cent, closing at 1,073.23, while the All T&T Index declined by 12.74 per cent, ending the year at 1,580.25. The Cross-Listed Index also saw a contraction of 7.74 per cent, closing at 74.28. Notably, however, the SME Index continued its upward trajectory for a third consecutive year, increasing by 30.91 per cent to end at 92.58.”

Given the performance of the SME Index last year, it is notable that the first IPO for 2025 is Medcorp, which proposes to be listed on the SME market.

Medcorp is an operator of private healthcare facilities located in north-west Trinidad, comprising:

* St. Clair Medical Centre (for acute care and specialised facilities);

* Goodhealth Medical Centre (for preventative and ambulatory care);

* The Brian Lara Cancer Treatment Centre (for oncology, radiotherapy and chemotherapy); and

* Doctors Radiology Centre (for diagnostic imaging).

There are several key features to the Medcorp offering of which potential investors in the company’s IPO should be aware:

1) Medcorp is a profitable company.

For the year ended December 31, 2024, the company declared profit before tax of $48.17 million, its taxation charge was $6.82 million (which is 14.24 per cent of its profit before tax) and its after-tax profit was $41.30 million.

According to the Medcorp prospectus, its net profit margin in its last four financial years was: 33.8 per cent—2024; 44.9 per cent—2023; 19.7 per cent—2022 and 21.4 per cent in 2021.

Medcorp’s net profit margin was adjusted in 2023 because “major shareholders elected to waive their dividend entitlements as part of the strategic preparation for Medcorp’s SME listing. When normalised for this non-recurring event, FY2023’s adjusted net profit margin was 20.8 per cent, consistent with historical performance.”

There was also an adjustment to the net profit margin in Medcorp’s 2024 financial year as the company amalgamated with its 100 per cent owned subsidiaries. That led to the company reducing its stated capital to improve the flexibility of the company’s capital structure and facilitate future capital needs and returns to shareholders.

“The shareholders subsequently waived their right to receive the full amount by which the stated capital was reduced and agreed to have this amount credited to the amalgamated company’s profit or loss,” according to the prospectus. The adjusted margin in 2024 was 12.6 per cent.

2) Healthy dividends

For the year ended December 31, 2023, certain shareholders to whom dividends were owed amounting to $30,694,185, irrevocably waived their right to receive the outstanding dividends. That means the company declared $30.69 million in dividends and “certain shareholders” decided to waive their right to receive the outstanding dividends thereafter.

The company also declared dividends of $29.92 million in 2024.

In its prospectus, Medcorp states that it will pay a dividend twice a year and the payout would be between 30 and 70 per cent of its after-tax profit.

3) Good ratios

Based on Medcorp’s $41.30 million after-tax profit in the financial year ended December 31, 2024, and with 7,479,977 shares in issue, the company’s earnings per share was $5.52 and its price to earnings (P/E) ratio for that period was 8.69X. That would be $48/$5.52.

If there is full subscription of the 350,000 shares on offer in the IPO at $48 per share, the earnings per share would be $5.28 and the PE ratio would be 9.10X.

Medcorp speaks

In a statement to the Business Guardian last Friday, Medcorp said the company has been the pioneer in healthcare delivery for years and is seeking to provide a unique opportunity for investors to diversify their portfolios into an essential sector that has historically demonstrated resilience during economic fluctuations.

“The way we see it, this IPO is simply extending that leadership into the financial markets. We’re offering something truly distinctive—the chance to own a stake in healthcare delivery without the enormous capital requirements of building hospitals or buying expensive medical equipment.

“Regarding the timing, we’re at an inflection point in our growth journey. The expansion of our new wing at Goodhealth Medical Centre and continuing investments in cutting-edge technology require capital, and this IPO provides that while positioning us for continued expansion. Additionally, we will remain vigilant regarding potential acquisition opportunities that align with our strategic objectives and value-creation criteria. Beyond our domestic initiatives, we will continue to develop medical tourism opportunities, strategic relationships, and satellite opportunities within the Caribbean region. The TTSE has provided us with additional capacity within our approved cap for future issuances, giving us flexibility as we grow.

“The initial offering may be perceived as a limited number of shares, but our approach is deliberate. Our valuation reflects our market leadership, unique positioning, and comprehensive service offering. We’ve structured our issuance this way to ensure strong performance upon market entry.

“The tax incentives available to companies that list on the TTSE SME market (the market on which Medcorp’s shares will be listed) should enhance our profitability beyond what historical financials might suggest. Additionally, being publicly traded brings three key benefits that directly impact our bottom line:

“First, enhanced brand recognition. When we become a publicly traded entity, our institutional profile is elevated substantially. This strengthens patient trust and stakeholder confidence, which we expect to translate directly into increased patient volume and revenue.

“Second, talent acquisition. As a public company, we can attract and retain the best professionals who want to deliver both clinical excellence and organizational stability. Having the best healthcare professionals means better care, better outcomes, and ultimately, better financial performance.

“Third, innovation funding. Ongoing access to capital markets ensures we can continue investing in medical innovations that improve patient outcomes. When we provide cutting-edge treatments not available elsewhere in T&T, we become the destination of choice for specialised care, expanding our market share and revenue streams.

“We’re particularly excited about creating opportunities for health professionals and others in the healthcare industry to build valuable relationship networks through investment. By becoming shareholders, industry professionals can strengthen connections while participating in our financial success.

“This is also an investment that resonates on a personal level. Healthcare touches everyone’s lives—we all require medical services, and these needs only increase as we age. By investing in Medcorp, shareholders are supporting an institution that has significantly reduced the need for citizens to seek medical care abroad. Quality healthcare is now available right here at home.

“Furthermore, Medcorp represents institutional stability and continuity. We are here for the long term. Our success doesn’t depend on any single individual or small group of people. We’ve established robust management structures and a sustainable operational model that will continue as a legacy for generations to come. This institutional strength is precisely what makes us an attractive market opportunity.

“This IPO represents a story of legacy, growth, and innovation. We refuse to rest on our laurels. To advance healthcare in Trinidad and Tobago, we must expand our capabilities and embrace new approaches. This public offering allows us to pursue exciting initiatives while embracing the transparency and accountability that come with being a public company.

“As good corporate citizens, we recognise our role extends beyond business operations. We’re proud to contribute to the national investment landscape, creating opportunities for citizens to build wealth while supporting vital healthcare services. This IPO isn’t just about Medcorp growing—it’s about expanding the opportunities for T&T’s investors and healthcare community to grow alongside us.

Disclosure: The author of this commentary is not a financial analyst. Nothing in this piece should be construed as providing financial advice to any potential investors, who are urged to seek such advice from professionals.

[pugboy]

if they wanted to raise $16m
they could just ask any big doc there and surely he could pull that out he wallet in a flash

they aint saying anything on succession planning with the senior mgmt getting older and some not well

[88sins]

Trinidad Guardian

Around the world, initial public offerings (IPOs) of shares in public companies are popular among investors because they present the potential for high returns, especially if the IPO is priced at a discount to its intrinsic value. IPOs also present an opportunity to invest in companies that are doing different things or doing things differently. And thirdly, IPOs allow for the diversification of an investor’s portfolio.

For most individual local investors, an IPO at this time is particularly useful, given the decline in the local stock market for the last three years.

Last year, according to the Trinidad and Tobago Stock Exchange’s latest annual report, “the local equity market faced a challenging environment, with most listed securities recording year-on-year price declines. This broad-based decline weighed heavily on the market indices.

“The Composite Index fell by 11.60 per cent, closing at 1,073.23, while the All T&T Index declined by 12.74 per cent, ending the year at 1,580.25. The Cross-Listed Index also saw a contraction of 7.74 per cent, closing at 74.28. Notably, however, the SME Index continued its upward trajectory for a third consecutive year, increasing by 30.91 per cent to end at 92.58.”

Given the performance of the SME Index last year, it is notable that the first IPO for 2025 is Medcorp, which proposes to be listed on the SME market.

Medcorp is an operator of private healthcare facilities located in north-west Trinidad, comprising:

* St. Clair Medical Centre (for acute care and specialised facilities);

* Goodhealth Medical Centre (for preventative and ambulatory care);

* The Brian Lara Cancer Treatment Centre (for oncology, radiotherapy and chemotherapy); and

* Doctors Radiology Centre (for diagnostic imaging).

There are several key features to the Medcorp offering of which potential investors in the company’s IPO should be aware:

1) Medcorp is a profitable company.

For the year ended December 31, 2024, the company declared profit before tax of $48.17 million, its taxation charge was $6.82 million (which is 14.24 per cent of its profit before tax) and its after-tax profit was $41.30 million.

According to the Medcorp prospectus, its net profit margin in its last four financial years was: 33.8 per cent—2024; 44.9 per cent—2023; 19.7 per cent—2022 and 21.4 per cent in 2021.

Medcorp’s net profit margin was adjusted in 2023 because “major shareholders elected to waive their dividend entitlements as part of the strategic preparation for Medcorp’s SME listing. When normalised for this non-recurring event, FY2023’s adjusted net profit margin was 20.8 per cent, consistent with historical performance.”

There was also an adjustment to the net profit margin in Medcorp’s 2024 financial year as the company amalgamated with its 100 per cent owned subsidiaries. That led to the company reducing its stated capital to improve the flexibility of the company’s capital structure and facilitate future capital needs and returns to shareholders.

“The shareholders subsequently waived their right to receive the full amount by which the stated capital was reduced and agreed to have this amount credited to the amalgamated company’s profit or loss,” according to the prospectus. The adjusted margin in 2024 was 12.6 per cent.

2) Healthy dividends

For the year ended December 31, 2023, certain shareholders to whom dividends were owed amounting to $30,694,185, irrevocably waived their right to receive the outstanding dividends. That means the company declared $30.69 million in dividends and “certain shareholders” decided to waive their right to receive the outstanding dividends thereafter.

The company also declared dividends of $29.92 million in 2024.

In its prospectus, Medcorp states that it will pay a dividend twice a year and the payout would be between 30 and 70 per cent of its after-tax profit.

3) Good ratios

Based on Medcorp’s $41.30 million after-tax profit in the financial year ended December 31, 2024, and with 7,479,977 shares in issue, the company’s earnings per share was $5.52 and its price to earnings (P/E) ratio for that period was 8.69X. That would be $48/$5.52.

If there is full subscription of the 350,000 shares on offer in the IPO at $48 per share, the earnings per share would be $5.28 and the PE ratio would be 9.10X.

Medcorp speaks

In a statement to the Business Guardian last Friday, Medcorp said the company has been the pioneer in healthcare delivery for years and is seeking to provide a unique opportunity for investors to diversify their portfolios into an essential sector that has historically demonstrated resilience during economic fluctuations.

“The way we see it, this IPO is simply extending that leadership into the financial markets. We’re offering something truly distinctive—the chance to own a stake in healthcare delivery without the enormous capital requirements of building hospitals or buying expensive medical equipment.

“Regarding the timing, we’re at an inflection point in our growth journey. The expansion of our new wing at Goodhealth Medical Centre and continuing investments in cutting-edge technology require capital, and this IPO provides that while positioning us for continued expansion. Additionally, we will remain vigilant regarding potential acquisition opportunities that align with our strategic objectives and value-creation criteria. Beyond our domestic initiatives, we will continue to develop medical tourism opportunities, strategic relationships, and satellite opportunities within the Caribbean region. The TTSE has provided us with additional capacity within our approved cap for future issuances, giving us flexibility as we grow.

“The initial offering may be perceived as a limited number of shares, but our approach is deliberate. Our valuation reflects our market leadership, unique positioning, and comprehensive service offering. We’ve structured our issuance this way to ensure strong performance upon market entry.

“The tax incentives available to companies that list on the TTSE SME market (the market on which Medcorp’s shares will be listed) should enhance our profitability beyond what historical financials might suggest. Additionally, being publicly traded brings three key benefits that directly impact our bottom line:

“First, enhanced brand recognition. When we become a publicly traded entity, our institutional profile is elevated substantially. This strengthens patient trust and stakeholder confidence, which we expect to translate directly into increased patient volume and revenue.

“Second, talent acquisition. As a public company, we can attract and retain the best professionals who want to deliver both clinical excellence and organizational stability. Having the best healthcare professionals means better care, better outcomes, and ultimately, better financial performance.

“Third, innovation funding. Ongoing access to capital markets ensures we can continue investing in medical innovations that improve patient outcomes. When we provide cutting-edge treatments not available elsewhere in T&T, we become the destination of choice for specialised care, expanding our market share and revenue streams.

“We’re particularly excited about creating opportunities for health professionals and others in the healthcare industry to build valuable relationship networks through investment. By becoming shareholders, industry professionals can strengthen connections while participating in our financial success.

“This is also an investment that resonates on a personal level. Healthcare touches everyone’s lives—we all require medical services, and these needs only increase as we age. By investing in Medcorp, shareholders are supporting an institution that has significantly reduced the need for citizens to seek medical care abroad. Quality healthcare is now available right here at home.

“Furthermore, Medcorp represents institutional stability and continuity. We are here for the long term. Our success doesn’t depend on any single individual or small group of people. We’ve established robust management structures and a sustainable operational model that will continue as a legacy for generations to come. This institutional strength is precisely what makes us an attractive market opportunity.

“This IPO represents a story of legacy, growth, and innovation. We refuse to rest on our laurels. To advance healthcare in Trinidad and Tobago, we must expand our capabilities and embrace new approaches. This public offering allows us to pursue exciting initiatives while embracing the transparency and accountability that come with being a public company.

“As good corporate citizens, we recognise our role extends beyond business operations. We’re proud to contribute to the national investment landscape, creating opportunities for citizens to build wealth while supporting vital healthcare services. This IPO isn’t just about Medcorp growing—it’s about expanding the opportunities for T&T’s investors and healthcare community to grow alongside us.

Disclosure: The author of this commentary is not a financial analyst. Nothing in this piece should be construed as providing financial advice to any potential investors, who are urged to seek such advice from professionals.

Funny thing about newspaper companies
Many of them will print whatever you tell them to, and whatever you pay them to.


Edit
I highly recommend you guys do your own math on this prior to investing if you are so inclined.

[pugboy]

them papers ppl not too bright

i recall they real big up the price plaza ipo which the owners say was to take advantage of the tax breaks for sme companies
yet they never question how a company with $600m assets could be considered sme
rahael and aboud make out like bandits with that one

[88sins]

is not so much that they not too bright.
is more like an "I'm being paid to make it look a certain way so that's what I doing no matter how it really is" type of scenario

Honestly, I does tell people, if you want to invest in stock in a company, your best options are to invest in financial, manufacturing, industrial, real estate, automotive, and precious metals sectors. Your investment is relatively more secure within those sectors.

But a service sector entity? Who in competition with the free government services? You stand a better chance of seeing your investment grow if you literally plant it in the yard and water it daily

[theview868]

Recently notice ttngl imdes going up
Any one think they gonna be worth buying in the future?

[snatman]

Agostini Limited has announced plans to acquire Prestige Holdings Limited through a share swap offer.

In a release today, Agostini's said under the arrangement shareholders of PHL will receive one Agostini share for every 4.8 PHL shares held.

Agostini said, "The offer represents a premium of approximately 31% over PHL’s 30-day average price (27% over today’s closing price). The offer will close at 4pm on July 21, 2025."

[theview868]

Agostini Limited has announced plans to acquire Prestige Holdings Limited through a share swap offer.

In a release today, Agostini's said under the arrangement shareholders of PHL will receive one Agostini share for every 4.8 PHL shares held.

Agostini said, "The offer represents a premium of approximately 31% over PHL’s 30-day average price (27% over today’s closing price). The offer will close at 4pm on July 21, 2025."

Yup prestige holdings share holders could benefit but then again motte stacking his assets

[theview868]

https://newsday.co.tt/2025/06/27/medcor ... ssful-ipo/

I see medcorp gt
According the reports it was fully subbed not over subbed ( interesting)

[88sins]

Wait and see who bought it

[pugboy]

in guardian papers today they talk about the success of the ipo for raising $16m, lol

as I suspected this is what it was all about, although they never said they were doing this to take advantage of the sme tax breaks
5 year tax holiday
Mor and dem smiling

but is revenue of $122m small enterprise ? plus assets of $300m
asking for a friend

them papers ppl not too bright

i recall they real big up the price plaza ipo which the owners say was to take advantage of the tax breaks for sme companies
yet they never question how a company with $600m assets could be considered sme
rahael and aboud make out like bandits with that one

[snatman]

that 50c special dividend from Prestige looking mighty fine.

[theview868]

that 50c special dividend from Prestige looking mighty fine.

You guys feel Agostini go buy out the share with newly updated info
Currently it increased to 96 percent of the all the phl shares .
Though phl recommends to take the swap

[pugboy]

medcorp price gone from $40 to $48 since ipo
they issue a $1 dividend payable in august

buyers wont be unhappy

[88sins]

medcorp price gone from $40 to $48 since ipo
they issue a $1 dividend payable in august

buyers wont be unhappy

IPO was 48 bro, not 40

[pugboy]

oh ho,
well i think it dropped to 40 because i saw in papers it was at 40

medcorp price gone from $40 to $48 since ipo
they issue a $1 dividend payable in august

buyers wont be unhappy

IPO was 48 bro, not 40

[pugboy]

yes, it appear to have dropped shortly after gone open public sale
looked at an old papers

[88sins]

Correct
And as of yesterday, it was 47
So despite the proposed $1 interim dividend, shareholders eh really make nothing

[pugboy]

so somebody decided they had to dump their shares very early at a discounted price
they must be needed cash bad

Correct
And as of yesterday, it was 47
So despite the proposed $1 interim dividend, shareholders eh really make nothing

[88sins]

Not necessarily
Could be for any of a myriad of reasons.

[originalbling]

AGL offer extended by a 2 weeks. Like they didn't meet the target.